Thursday, November 14, 2013

Biosensors : Power of BIG believing (CIMB)

Biosensors Int'l
Current S$0.93
Target S$1.19
Power of BIG believing

▊ BIG’s weaker results could prompt the market to further downgrade the stock. However, we see bright spots in Spectrum Dynamics’ instant success, a more disciplined approach to future spending and the positives that regulatory approvals and new launches could bring. At 32% of our FY14 forecast, 1HFY3/14 core EPS missed our below-consensus estimates due to lower licensing income and higher opex. We slash FY14-16 EPS by 19-35% for lower sales assumptions and cut our SOP-based target price by 10%. Our contrarian Outperform rating hinges on the instant success of Spectrum Dynamics, product launches, regulatory approvals and M&A accretion.


Not big in Japan anymore
2QFY14 results came in at just 15% of our full-year forecast because of 1) a 25% decline in licensing revenue due to continued challenges in Japan, and 2) higher operating expenditure from SG&A that arises from the costly brand-building exercise, though better cost measures have been put in place.

Pleasing volume recovery
As with volume growth in the EMEA and APAC regions, DES sales in China improved significantly (by double digits according to management). We believe that ASP weakness persists, leading management to downgrade its FY14 revenue growth guidance from 15% to “moderate”. Our main grouse is that there is not much room for improvement in licensing and royalty income in the next few quarters.

Contrarian positive view
We think BIG’s cheaper valuation only prices in the near-term challenges and understates the earnings uplift from the commercialisation of new products in FY15. Additionally, Spectrum Dynamics will boost earnings when it gets approval from China’s Food and Drug Administration. BIG is working on multiple product launches to generate new revenues for the company. Other products are gaining ground with various regulatory approvals and the soft launch of BioFreedom remains a source of excitement.



Source/Extract/Excerpts/来源/转贴/摘录: CIMB-Research,
Publish date:13/11/13

No comments:

Post a Comment

Warren E. Buffett(沃伦•巴菲特)
Be fearful when others are greedy, and be greedy when others are fearful
别人贪婪时我恐惧, 别人恐惧时我贪婪
投资只需学好两门课: 一,是如何给企业估值,二,是如何看待股市波动
吉姆·罗杰斯(Jim Rogers)
“错过时机”胜于“搞错对象”:不会全军覆没!”
做自己熟悉的事,等到发现大好机会才投钱下去

乔治·索罗斯(George Soros)

“犯错误并没有什么好羞耻的,只有知错不改才是耻辱。”

如果操作过量,即使对市场判断正确,仍会一败涂地。

李驰(中国巴菲特)
高估期间, 卖对, 不卖也对, 买是错的。
低估期间, 买对, 不买也是对, 卖是错的。

Tan Teng Boo


There’s no such thing as defensive stocks.Every stock can be defensive depending on what price you pay for it and what value you get,
冷眼(冯时能)投资概念
“买股票就是买公司的股份,买股份就是与陌生人合股做生意”。
合股做生意,则公司股份的业绩高于一切,而股票的价值决定于盈利。
价值是本,价格是末,故公司比股市重要百倍。
曹仁超-香港股神/港股明灯
1.有智慧,不如趁势
2.止损不止盈
成功者所以成功,是因为不怕失败!失败者所以失败,是失败后不再尝试!
曾淵滄-散户明灯
每逢灾难就是机会,而是在灾难发生时贱价买股票,然后放在一边,耐性地等灾难结束
  • Selected Indexes 52 week range

  • Margin of Safety

    Investment Clock

    World's First Interactive Investment Clock